GlassScriptPhysician profile
Mohamed Sebai
NPI 1760481915
$8,649.61
in general payments reported to CMS, 2019-2025
24 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $886 · 2021: $1,255 · 2022: $777 · 2023: $1,091 · 2024: $1,351 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,897.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,249.01 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Janssen Biotech, INC. | $1,093.29 | 2019-2025 | Tremfya |
| Abbvie INC. | $826.78 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Glaxosmithkline, LLC. | $818.32 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $687.60 | 2019-2025 | |
| Pfizer INC. | $600.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $479.34 | 2019-2024 | Orencia |
| Genentech USA, INC. | $345.33 | 2019-2023 | Actemra |
| Ucb, INC. | $255.47 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $212.94 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $202.35 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $186.12 | 2019-2023 | Taltz |
| US Oncology Corporate, INC. | $173.84 | 2024 | |
| Genzyme Corporation | $98.87 | 2019-2025 | |
| Organon LLC | $75.38 | 2023-2025 | Renflexis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.66 | 2020-2024 | Ofev |
| Fresenius Kabi USA, LLC | $61.46 | 2023 | Idacio |
| Medexus Pharma, INC. | $57.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.11 | 2021-2022 | |
| Radius Health, INC. | $37.10 | 2020-2023 | |
| Sandoz INC. | $29.80 | 2024 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $26.16 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $20.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Sebai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.